On December 11, 000881.SZ announced a resolution of the 12th meeting of the Ninth Board of Directors of the company to consider and adopt the "Bill on the newly established China Guangzhou Nuclear Medical Technology Co., Ltd. (tentative name)."

After consideration, the board of directors agreed that the company and the people's Government of Youxian District of Mianyang City should sign the Investment Agreement on the Proton Medical equipment Manufacturing Base of Zhongguang Nuclear Technology Development Co., Ltd. (Mianyang). It is agreed that the wholly-owned subsidiary of the company, Zhongguang Nuclear Dasheng Accelerator Technology Co., Ltd. will contribute 500 million yuan to set up its wholly-owned subsidiary Zhongguang Nuclear Medical Technology Co., Ltd. (tentative name, subject to the registration and filing name of the industry and commerce department).

Proton tumor therapy system is a kind of three types of medical devices supervised by the State Food and Drug Administration and a kind of X-ray device supervised by the State Nuclear Safety Administration. It is also a large-scale medical equipment supervised by the State Health Commission under the supervision of Class A configuration license. The pre-cultivation of this business has always relied on the wholly-owned subsidiary Zhongguang Nuclear Dasheng Accelerator Technology Co., Ltd., but in view of the signing of the license agreement for proton therapy technology and the proposed landing of proton medical equipment manufacturing base in Mianyang, it is necessary to form a separate legal entity. In order to obtain the corresponding qualifications, adapt to the standards, norms and requirements of the medical equipment manufacturing industry, meet the demands of market development, apply for industry and scientific research subsidies, and recruit corresponding professional teams, and targeted to develop assessment objectives, business objectives, development path. After the establishment of the new company, the rights and obligations of the authorization of proton therapy oncology technology will be completely transferred to the new company.